WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsSophia Genetics SA (SOPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 3635% more annual revenue ($2.89B vs $77.27M). MMED leads profitability with a -7.3% profit margin vs -102.2%. MMED earns a higher WallStSmart Score of 37/100 (F).

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

SOPH

Avoid

26

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -3.43

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED0 strengths · Avg: 0/10

No standout strengths identified

SOPH1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
22.4%8/10

Revenue surging 22.4% year-over-year

Areas to Watch

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

SOPH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$371.96M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.043/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : SOPH

The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Bear Case : SOPH

The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while SOPH is a growth play — different risk/reward profiles.

SOPH is growing revenue faster at 22.4% — sustainability is the question.

SOPH generates stronger free cash flow (-9M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMED scores higher overall (37/100 vs 26/100) and 13.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Sophia Genetics SA

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Sophia Genetics SA (SOPH) is a pioneering leader in data-driven medicine, focusing on advanced genomic and clinical data analytics that enhance patient outcomes. Utilizing cutting-edge machine learning algorithms, the company provides a comprehensive platform that aids hospitals and laboratories in interpreting complex genomic data, thus facilitating personalized treatment strategies, especially in oncology, rare diseases, and hereditary disorders. With a strong international footprint and strategic partnerships with premier healthcare organizations, Sophia Genetics is committed to transforming healthcare through precision medicine, solidifying its position as a front-runner in the genomics landscape.

Want to dig deeper into these stocks?